Assessing Risk Factors for PsA Development in Patients With Psoriasis

November 26th 2021, 6:00pm


Use of biologics and age may influence risk of psoriatic arthritis (PsA) development in patients with psoriasis, according to findings presented at the 2021 American College of Rheumatology Annual Meeting.

Greater Work Impairment, Comorbidity Burden Linked With Concomitant Psoriasis, PsA

November 20th 2021, 7:00pm


Findings presented at the 2021 American College of Rheumatology Annual Meeting showed that patients with concomitant psoriasis and psoriatic arthritis (PsA) reported greater incidence of obesity, hypertension, and diabetes, as well as a higher likelihood of work inability than those with only psoriasis.

Guselkumab Linked With Long-term Improvement of Joint Manifestations, Disease Activity in PsA

November 17th 2021, 4:30pm


Phase 3 findings of the DISCOVER-2 trial presented at the 2021 American College of Rheumatology Annual Meeting indicated that guselkumab (Tremfya) provided long-term improvement in joint manifestations, disease activity, and physical function among patients with psoriatic arthritis who had no prior biologic treatment.

Prior Biologic Use, Body Weight May Impact Guselkumab Efficacy in Psoriasis

November 12th 2021, 6:45pm


Real-world patients with moderate-to-severe psoriasis were shown to exhibit impaired efficacy with guselkumab treatment if they had history of prior biologic use, particularly anti-interleukin (IL)-17 exposure, with heavier patients linked with delayed onset of therapeutic response.

Real-world Findings Show Apremilast Effective Long Term in Plaque Psoriasis

November 9th 2021, 8:30pm


Findings of a real-world, single-center study indicated that apremilast was effective and safe long-term in the treatment of moderate-to-severe plaque psoriasis.

Ixekizumab Linked With Improved Outcomes vs Adalimumab in PsA With Concomitant Psoriasis

November 3rd 2021, 4:30pm


A greater proportion of biologic-naive patients with psoriatic arthritis treated with ixekizumab vs adalimumab achieved the combined endpoint of 100% resolution in the Psoriasis Area Severity Index and 50% or greater improvement in the American College of Rheumatology criteria at week 24 and 52.

Economic Burden of Joint Disease in Psoriasis: US Claims Analysis

November 1st 2021, 1:00pm


This retrospective claims analysis found that concomitant joint disease in psoriasis is associated with greater health care resource utilization and health care costs than psoriasis alone.

Biologic Treatment, Smoking May Increase Psoriasis Risk in Patients With IBD

October 29th 2021, 4:00pm


Patients with inflammatory bowel disease (IBD) treated with adalimumab had greater risk of developing psoriasis than those administered infliximab, with gender and smoking incidence also linked with greater IBD risk.

Biologic, Antirheumatic Drug Use May Increase Risk of Adverse Pregnancy Outcomes in Women With Psoriasis

October 26th 2021, 1:00pm


Pregnant women with psoriasis were found to be at increased risk of experiencing preterm birth and Cesarean delivery, with patients undergoing anti-rheumatic treatment during their first pregnancy indicated to be at significantly greater risk.

AMCP Studies Highlight Workplace Costs of Skin Care

October 21st 2021, 4:17pm


Studies presented at Academy of Managed Care Pharmacy Nexus 2021 elucidated costs of skin treatment for workers in terms of recovery time taken and percentage of salary.